Meeting
2019 Genitourinary Cancers Symposium
The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.
Authors
Tatsuya Shimomura
Jikei University School of Medicine, Tokyo, Japan
Tatsuya Shimomura , Keiichiro Mori , Toshihiro Yamamoto , Hajime Onuma , Hiroyuki Inaba , Kenichi Hata , Takahiro Kimura , Shin Egawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 315)
DOI
10.1200/JCO.2019.37.7_suppl.315
Abstract #
315
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Exploring optimal sequence of abiraterone and enzalutamide in patients with castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
First Author: Naoki Terada
Poster
2020 Genitourinary Cancers Symposium
Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.
First Author: Giorgia Gurioli
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
First Author: Mary-Ellen Taplin